Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.12
LCI's Cash-to-Debt is ranked lower than
88% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. LCI: 0.12 )
Ranked among companies with meaningful Cash-to-Debt only.
LCI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.64 Max: 211.9
Current: 0.12
0
211.9
Equity-to-Asset 0.38
LCI's Equity-to-Asset is ranked lower than
81% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. LCI: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
LCI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.05  Med: 0.62 Max: 0.91
Current: 0.38
-1.05
0.91
Debt-to-Equity 1.40
LCI's Debt-to-Equity is ranked lower than
91% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. LCI: 1.40 )
Ranked among companies with meaningful Debt-to-Equity only.
LCI' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.88  Med: 0.11 Max: 9.27
Current: 1.4
-3.88
9.27
Debt-to-EBITDA 4.38
LCI's Debt-to-EBITDA is ranked lower than
72% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. LCI: 4.38 )
Ranked among companies with meaningful Debt-to-EBITDA only.
LCI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.54 Max: 6.57
Current: 4.38
0
6.57
Interest Coverage 2.07
LCI's Interest Coverage is ranked lower than
91% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. LCI: 2.07 )
Ranked among companies with meaningful Interest Coverage only.
LCI' s Interest Coverage Range Over the Past 10 Years
Min: 2.07  Med: 33.41 Max: 1115.01
Current: 2.07
2.07
1115.01
Piotroski F-Score: 7
Altman Z-Score: 1.36
Beneish M-Score: -2.36
WACC vs ROIC
0.44%
7.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 25.90
LCI's Operating Margin % is ranked higher than
90% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. LCI: 25.90 )
Ranked among companies with meaningful Operating Margin % only.
LCI' s Operating Margin % Range Over the Past 10 Years
Min: -1.1  Med: 19.16 Max: 56.73
Current: 25.9
-1.1
56.73
Net Margin % 4.19
LCI's Net Margin % is ranked higher than
56% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. LCI: 4.19 )
Ranked among companies with meaningful Net Margin % only.
LCI' s Net Margin % Range Over the Past 10 Years
Min: -0.26  Med: 5.87 Max: 36.85
Current: 4.19
-0.26
36.85
ROE % 4.89
LCI's ROE % is ranked higher than
56% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. LCI: 4.89 )
Ranked among companies with meaningful ROE % only.
LCI' s ROE % Range Over the Past 10 Years
Min: -0.28  Med: 8.85 Max: 39.56
Current: 4.89
-0.28
39.56
ROA % 1.78
LCI's ROA % is ranked higher than
50% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. LCI: 1.78 )
Ranked among companies with meaningful ROA % only.
LCI' s ROA % Range Over the Past 10 Years
Min: -0.19  Med: 4.71 Max: 35.21
Current: 1.78
-0.19
35.21
ROC (Joel Greenblatt) % 27.33
LCI's ROC (Joel Greenblatt) % is ranked higher than
77% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. LCI: 27.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LCI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -0.8  Med: 27.31 Max: 133.12
Current: 27.33
-0.8
133.12
3-Year Revenue Growth Rate 17.90
LCI's 3-Year Revenue Growth Rate is ranked higher than
91% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. LCI: 17.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LCI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.8  Med: 15.55 Max: 91.7
Current: 17.9
-20.8
91.7
3-Year EBITDA Growth Rate -7.20
LCI's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. LCI: -7.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LCI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.25 Max: 153.4
Current: -7.2
0
153.4
3-Year EPS without NRI Growth Rate -43.00
LCI's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. LCI: -43.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LCI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.4 Max: 206.7
Current: -43
0
206.7
GuruFocus has detected 2 Warning Signs with Lannett Co Inc LCI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LCI's 30-Y Financials

Financials (Next Earnings Date: 2018-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

LCI Guru Trades in Q3 2017

Chuck Royce 590 sh (New)
Richard Snow 3,435,152 sh (+8.97%)
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 454,873 sh (-6.42%)
» More
Q4 2017

LCI Guru Trades in Q4 2017

Paul Tudor Jones 9,331 sh (New)
Steven Cohen 84,037 sh (New)
Ronald Muhlenkamp 433,134 sh (-4.78%)
Richard Snow 3,037,816 sh (-11.57%)
Chuck Royce 396 sh (-32.88%)
» More
Q1 2018

LCI Guru Trades in Q1 2018

Chuck Royce 694 sh (+75.25%)
Paul Tudor Jones Sold Out
Richard Snow 2,781,693 sh (-8.43%)
Ronald Muhlenkamp 272,623 sh (-37.06%)
Steven Cohen 35,337 sh (-57.95%)
» More
Q2 2018

LCI Guru Trades in Q2 2018

Paul Tudor Jones 20,050 sh (New)
Pioneer Investments 790,000 sh (New)
Chuck Royce 1,181 sh (+70.17%)
Steven Cohen 35,337 sh (unchged)
Ronald Muhlenkamp 272,442 sh (-0.07%)
Richard Snow 2,410,090 sh (-13.36%)
» More
» Details

Insider Trades

Latest Guru Trades with LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2018-06-30 Reduce -0.07%$13.3 - $17.45 $ 5.50-65%272,442
Ronald Muhlenkamp 2018-03-31 Reduce -37.06%1.1%$14.7 - $24.95 $ 5.50-71%272,623
Ronald Muhlenkamp 2017-12-31 Reduce -4.78%0.13%$19.9 - $29.25 $ 5.50-77%433,134
Ronald Muhlenkamp 2017-09-30 Reduce -6.42%0.2%$15.1 - $22.7 $ 5.50-70%454,873
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:CAI:PHAR, SHSE:603168, XKRX:092040, XKRX:086450, XKRX:271980, XKRX:229500, BOM:530549, TSXV:THCX, SZSE:002728, TSX:CMED, TSE:3151, LSE:APH, SZSE:000790, SZSE:300702, SZSE:300436, XKRX:222040, SZSE:002923, NAS:RIGL, SZSE:300519, SZSE:002750 » details
Traded in other countries:LN5.Germany,
Headquarter Location:USA
Lannett Co Inc develops, manufactures, packages, markets and distributes generic versions of branded pharmaceutical products. Its products include solid oral dosage forms, including oral solutions, nasal, topicals or parentarels.

Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. It offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It also provides its products for various medical indications comprising glaucoma, Gastrointestinal, Migraine, Obesity, and Respiratory.

Top Ranked Articles about Lannett Co Inc

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO, LCI, CBS, PZZA, SKX, CRON, PM and QRTEA
Hagens Berman Reminds Investors in Lannett Company, Inc. (NYSE: LCI) of the October 26, 2018 Securities Class Action Lead Plaintiff Deadline
SHAREHOLDER ALERT: TSLA PDD LCI CBS ORCL SBGI HMNY PVG OPK USAT TRCO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, CBS and FB
SHAREHOLDER ALERT: AMPE NVRO LCI CBS PZZA FIZZ CRON PM QRTEA OPK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline – LCI
LCI LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Lannett Company, Inc. - LCI
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, ACAD and FB
SHAREHOLDER ALERT: TSLA LCI CBS ORCL LOGM NLSN ZN RMTI HMNY SKX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Richard Snow Slashes Lannett Stake by 85% Pharmaceutical company recently lost major supplier
Snow Capital Management leader Richard Snow (Trades, Portfolio) disclosed this week that he reduced his Lannett Co. Inc. (NYSE:LCI) position by 84.76% on Aug. 21. Read more...

Ratios

vs
industry
vs
history
PE Ratio 7.45
LCI's PE Ratio is ranked higher than
89% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. LCI: 7.45 )
Ranked among companies with meaningful PE Ratio only.
LCI' s PE Ratio Range Over the Past 10 Years
Min: 6.4  Med: 22 Max: 222.5
Current: 7.45
6.4
222.5
Forward PE Ratio 2.32
LCI's Forward PE Ratio is ranked higher than
98% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. LCI: 2.32 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 7.45
LCI's PE Ratio without NRI is ranked higher than
89% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. LCI: 7.45 )
Ranked among companies with meaningful PE Ratio without NRI only.
LCI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.4  Med: 22 Max: 222.5
Current: 7.45
6.4
222.5
Price-to-Owner-Earnings 12.84
LCI's Price-to-Owner-Earnings is ranked higher than
96% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.95 vs. LCI: 12.84 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LCI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.44  Med: 18.16 Max: 834.91
Current: 12.84
4.44
834.91
PB Ratio 0.34
LCI's PB Ratio is ranked higher than
92% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. LCI: 0.34 )
Ranked among companies with meaningful PB Ratio only.
LCI' s PB Ratio Range Over the Past 10 Years
Min: 0.3  Med: 1.5 Max: 6.39
Current: 0.34
0.3
6.39
PS Ratio 0.30
LCI's PS Ratio is ranked higher than
88% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. LCI: 0.30 )
Ranked among companies with meaningful PS Ratio only.
LCI' s PS Ratio Range Over the Past 10 Years
Min: 0.27  Med: 1.29 Max: 7.1
Current: 0.3
0.27
7.1
Price-to-Free-Cash-Flow 4.50
LCI's Price-to-Free-Cash-Flow is ranked higher than
95% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. LCI: 4.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LCI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.22  Med: 17.21 Max: 213.77
Current: 4.5
3.22
213.77
Price-to-Operating-Cash-Flow 1.80
LCI's Price-to-Operating-Cash-Flow is ranked higher than
97% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. LCI: 1.80 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LCI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.53  Med: 13.51 Max: 288.5
Current: 1.8
1.53
288.5
EV-to-EBIT 6.97
LCI's EV-to-EBIT is ranked higher than
89% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. LCI: 6.97 )
Ranked among companies with meaningful EV-to-EBIT only.
LCI' s EV-to-EBIT Range Over the Past 10 Years
Min: -277  Med: 11.35 Max: 398
Current: 6.97
-277
398
EV-to-EBITDA 4.98
LCI's EV-to-EBITDA is ranked higher than
92% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. LCI: 4.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
LCI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -748.5  Med: 10 Max: 3667
Current: 4.98
-748.5
3667
EV-to-Revenue 1.39
LCI's EV-to-Revenue is ranked higher than
71% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. LCI: 1.39 )
Ranked among companies with meaningful EV-to-Revenue only.
LCI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 1.7 Max: 7.6
Current: 1.39
0.4
7.6
PEG Ratio 0.23
LCI's PEG Ratio is ranked higher than
97% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. LCI: 0.23 )
Ranked among companies with meaningful PEG Ratio only.
LCI' s PEG Ratio Range Over the Past 10 Years
Min: 0.07  Med: 0.37 Max: 16.62
Current: 0.23
0.07
16.62
Shiller PE Ratio 5.94
LCI's Shiller PE Ratio is ranked higher than
89% of the 252 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.75 vs. LCI: 5.94 )
Ranked among companies with meaningful Shiller PE Ratio only.
LCI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 5.12  Med: 68.67 Max: 1389
Current: 5.94
5.12
1389
Current Ratio 2.62
LCI's Current Ratio is ranked higher than
53% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. LCI: 2.62 )
Ranked among companies with meaningful Current Ratio only.
LCI' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.07 Max: 8.51
Current: 2.62
0.96
8.51
Quick Ratio 1.92
LCI's Quick Ratio is ranked higher than
51% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. LCI: 1.92 )
Ranked among companies with meaningful Quick Ratio only.
LCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.58 Max: 7.45
Current: 1.92
0.39
7.45
Days Inventory 121.44
LCI's Days Inventory is ranked lower than
59% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. LCI: 121.44 )
Ranked among companies with meaningful Days Inventory only.
LCI' s Days Inventory Range Over the Past 10 Years
Min: 68.82  Med: 116.68 Max: 165.34
Current: 121.44
68.82
165.34
Days Sales Outstanding 134.71
LCI's Days Sales Outstanding is ranked lower than
80% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. LCI: 134.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
LCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 78.9  Med: 108.89 Max: 142.45
Current: 134.71
78.9
142.45
Days Payable 52.34
LCI's Days Payable is ranked lower than
53% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. LCI: 52.34 )
Ranked among companies with meaningful Days Payable only.
LCI' s Days Payable Range Over the Past 10 Years
Min: 49.15  Med: 70.31 Max: 88.36
Current: 52.34
49.15
88.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
LCI's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. LCI: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37  Med: -5.3 Max: 26.7
Current: -1
-37
26.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.14
LCI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. LCI: 0.14 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LCI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.12  Med: 1.35 Max: 5.86
Current: 0.14
0.12
5.86
Price-to-Median-PS-Value 0.24
LCI's Price-to-Median-PS-Value is ranked higher than
77% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. LCI: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LCI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 1.09 Max: 8.62
Current: 0.24
0.2
8.62
Price-to-Peter-Lynch-Fair-Value 0.30
LCI's Price-to-Peter-Lynch-Fair-Value is ranked higher than
92% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.41 vs. LCI: 0.30 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LCI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.94 Max: 2.03
Current: 0.3
0.26
2.03
Earnings Yield (Greenblatt) % 14.32
LCI's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. LCI: 14.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LCI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.2  Med: 6.5 Max: 20
Current: 14.32
-13.2
20
Forward Rate of Return (Yacktman) % 59.94
LCI's Forward Rate of Return (Yacktman) % is ranked higher than
99% of the 421 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.96 vs. LCI: 59.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LCI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.7  Med: 8.6 Max: 59.94
Current: 59.94
0.7
59.94

More Statistics

Revenue (TTM) (Mil) $684.56
EPS (TTM) $ 0.74
Beta1.44
Volatility75.22%
52-Week Range $4.60 - 30.35
Shares Outstanding (Mil)38.90

Analyst Estimate

Jun19 Jun20 Jun21
Revenue (Mil $) 592 471 432
EBIT (Mil $)
EBITDA (Mil $) 189 128 125
EPS ($) 1.57 0.44 0.74
EPS without NRI ($) 1.57 0.44 0.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}